適用於治療曾接受過至少一次全身性療法，且帶有KRAS G12C突變之局部晚期或轉移性非小細胞肺癌(NSCLC)成年病人。

Antineoplastic Agent, KRAS Inhibitor

Distribution: 211 L.
Protein binding: 89%.
Metabolism: nonenzymatic conjugation and oxidative metabolism via CYP3As.
Half-life elimination: 5 hours.
Time to peak: median: 1 hour.
Excretion: feces: 74%; urine: 6%.
Clearance: 26.2 L/hour.

Hypersensitivity to sotorasib or any component of the formulation.

>10%: edema (15%), skin rash (12%), decreased serum albumin (22%), decreased serum calcium (35%), decreased serum sodium (28%), abdominal pain (15%), diarrhea (42%), nausea (26%), vomiting (17%), increase in urinary protein (29%), decreased hemoglobin (43%), lymphocytopenia (48%), prolonged partial thromboplastin time (23%), hepatotoxicity (25%), increased serum alanine aminotransferase (38%), increased serum alkaline phosphatase (33%), increased serum aspartate aminotransferase (39%), fatigue (26%), arthralgia (12%), musculoskeletal pain (35%), cough (20%), dyspnea (16%), pneumonia (12%).

960 mg (8 tab) once daily.

---

Recommended Lumakras dose reductions based on adverse reactions

dose	reduction dose
first dose reduction	480 mg (4 tab) once daily
second dose reduction	240 mg (2 tab) once daily